Psoriasis of Scalp Clinical Trial
Official title:
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of
calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more
effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50
mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis.
The primary outcome is the proportion of patients with absence of disease or very mild
disease after 8 weeks of treatment.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00243464 -
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
|
Phase 3 | |
| Recruiting |
NCT05144165 -
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
|
||
| Completed |
NCT05105139 -
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
|
||
| Recruiting |
NCT04099979 -
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
|
||
| Not yet recruiting |
NCT03553433 -
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
|
Phase 4 | |
| Recruiting |
NCT05938361 -
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
|
||
| Recruiting |
NCT05858632 -
Immune Spatial Features of Guselkumab Cutaneous Response
|
Phase 4 | |
| Completed |
NCT00216879 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis
|
Phase 3 | |
| Completed |
NCT00216840 -
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis
|
Phase 3 |